200 related articles for article (PubMed ID: 32066715)
41. Burden of Treatment Resistant Depression (TRD) in patients with major depressive disorder in Ontario using Institute for Clinical Evaluative Sciences (ICES) databases: Economic burden and healthcare resource utilization.
McIntyre RS; Millson B; Power GS
J Affect Disord; 2020 Dec; 277():30-38. PubMed ID: 32791390
[TBL] [Abstract][Full Text] [Related]
42. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA
Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539512
[TBL] [Abstract][Full Text] [Related]
43. Polymorphisms of COMT and CREB1 are associated with treatment-resistant depression in a Chinese Han population.
Wang Y; Li S; Niu L; Ma Y; Qiu Y; Li S; Guobule N; Cao H; Li J
J Neural Transm (Vienna); 2022 Jan; 129(1):85-93. PubMed ID: 34767111
[TBL] [Abstract][Full Text] [Related]
44. Using a machine learning approach to investigate factors associated with treatment-resistant depression among adults with chronic non-cancer pain conditions and major depressive disorder.
Shah D; Zheng W; Allen L; Wei W; LeMasters T; Madhavan S; Sambamoorthi U
Curr Med Res Opin; 2021 May; 37(5):847-859. PubMed ID: 33686881
[TBL] [Abstract][Full Text] [Related]
45. Low-dose ketamine for treatment resistant depression in an academic clinical practice setting.
Feifel D; Malcolm B; Boggie D; Lee K
J Affect Disord; 2017 Oct; 221():283-288. PubMed ID: 28666206
[TBL] [Abstract][Full Text] [Related]
46. Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis.
Pilon D; Joshi K; Sheehan JJ; Zichlin ML; Zuckerman P; Lefebvre P; Greenberg PE
PLoS One; 2019; 14(10):e0223255. PubMed ID: 31600244
[TBL] [Abstract][Full Text] [Related]
47. Socio-demographic and clinical predictors of non-response/non-remission in treatment resistant depressed patients: A systematic review.
De Carlo V; Calati R; Serretti A
Psychiatry Res; 2016 Jun; 240():421-430. PubMed ID: 27155594
[TBL] [Abstract][Full Text] [Related]
48. Refining Prediction in Treatment-Resistant Depression: Results of Machine Learning Analyses in the TRD III Sample.
Kautzky A; Dold M; Bartova L; Spies M; Vanicek T; Souery D; Montgomery S; Mendlewicz J; Zohar J; Fabbri C; Serretti A; Lanzenberger R; Kasper S
J Clin Psychiatry; 2018; 79(1):. PubMed ID: 29228516
[TBL] [Abstract][Full Text] [Related]
49. Investigating genetic overlap between antidepressant and lithium response and treatment resistance in major depressive disorder.
Lu Y; Xiong Y; Karlsson R; Song J; Kowalec K; Rück C; Sigstrom R; Jonsson L; Clements C; Andersson E; Boberg J; Lewis C; Sullivan P; Landén M
Res Sq; 2023 Feb; ():. PubMed ID: 36865283
[TBL] [Abstract][Full Text] [Related]
50. Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database.
Kubitz N; Mehra M; Potluri RC; Garg N; Cossrow N
PLoS One; 2013; 8(10):e76882. PubMed ID: 24204694
[TBL] [Abstract][Full Text] [Related]
51. Descriptive analysis of the economic burden of treatment resistance in a major depressive episode.
Cai Q; Sheehan JJ; Wu B; Alphs L; Connolly N; Benson C
Curr Med Res Opin; 2020 Feb; 36(2):329-335. PubMed ID: 31540559
[No Abstract] [Full Text] [Related]
52. Economic burden of treatment-resistant depression in privately insured US patients with co-occurring anxiety disorder and/or substance use disorder.
Zhdanava M; Kuvadia H; Joshi K; Daly E; Pilon D; Rossi C; Morrison L; Lefebvre P; Nelson C
Curr Med Res Opin; 2021 Jan; 37(1):123-133. PubMed ID: 33124940
[TBL] [Abstract][Full Text] [Related]
53. Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis.
Tansey KE; Guipponi M; Perroud N; Bondolfi G; Domenici E; Evans D; Hall SK; Hauser J; Henigsberg N; Hu X; Jerman B; Maier W; Mors O; O'Donovan M; Peters TJ; Placentino A; Rietschel M; Souery D; Aitchison KJ; Craig I; Farmer A; Wendland JR; Malafosse A; Holmans P; Lewis G; Lewis CM; Stensbøl TB; Kapur S; McGuffin P; Uher R
PLoS Med; 2012; 9(10):e1001326. PubMed ID: 23091423
[TBL] [Abstract][Full Text] [Related]
54. Blood transcriptional response to treatment-resistant depression during electroconvulsive therapy.
Israel-Elgali I; Hertzberg L; Shapira G; Segev A; Krieger I; Nitzan U; Bloch Y; Pillar N; Mayer O; Weizman A; Gurwitz D; Shomron N
J Psychiatr Res; 2021 Sep; 141():92-103. PubMed ID: 34182381
[TBL] [Abstract][Full Text] [Related]
55. Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression.
Jesus-Nunes AP; Leal GC; Correia-Melo FS; Vieira F; Mello RP; Caliman-Fontes AT; Echegaray MVF; Marback RF; Guerreiro-Costa LNF; Souza-Marques B; Santos-Lima C; Souza LS; Bandeira ID; Kapczinski F; Lacerda ALT; Quarantini LC
Hum Psychopharmacol; 2022 Jul; 37(4):e2836. PubMed ID: 35179810
[TBL] [Abstract][Full Text] [Related]
56. Frequency-specific alterations in functional connectivity in treatment-resistant and -sensitive major depressive disorder.
He Z; Cui Q; Zheng J; Duan X; Pang Y; Gao Q; Han S; Long Z; Wang Y; Li J; Wang X; Zhao J; Chen H
J Psychiatr Res; 2016 Nov; 82():30-9. PubMed ID: 27459030
[TBL] [Abstract][Full Text] [Related]
57. Antidepressant-resistant depression is characterized by reduced short- and long-interval cortical inhibition.
Jeng JS; Li CT; Lin HC; Tsai SJ; Bai YM; Su TP; Chang YW; Cheng CM
Psychol Med; 2020 Jun; 50(8):1285-1291. PubMed ID: 31155020
[TBL] [Abstract][Full Text] [Related]
58. N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trial.
Yang C; Bosker FJ; Li J; Schoevers RA
BMC Psychiatry; 2018 Sep; 18(1):279. PubMed ID: 30176835
[TBL] [Abstract][Full Text] [Related]
59. Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study.
Wu Z; Chen J; Yuan C; Hong W; Peng D; Zhang C; Cao L; Fang Y
J Affect Disord; 2013 Sep; 150(3):834-9. PubMed ID: 23570952
[TBL] [Abstract][Full Text] [Related]
60. Prevalence and Impact of Treatment-Resistant Depression in Latin America: a Prospective, Observational Study.
Soares B; Kanevsky G; Teng CT; Pérez-Esparza R; Bonetto GG; Lacerda ALT; Uribe ES; Cordoba R; Lupo C; Samora AM; Cabrera P
Psychiatr Q; 2021 Dec; 92(4):1797-1815. PubMed ID: 34463905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
